Current therapy of ulcerative colitis in children

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 1, 2004, Pages 37-53

  Bremner, Alan Ronald ^a   Griffiths, David Mervyn ^b   Beattie, Robert Mark ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Children; Immunosuppression; Inflammatory bowel disease; Therapy; Ulcerative colitis

Indexed keywords

'PREDENEMA'; AZATHIOPRINE; BALSALAZIDE; BASILIXIMAB; BECLOMETASONE DIPROPIONATE; BUDENOFALK; BUDESONIDE; BUTYRIC ACID; CALCIUM; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; EPIDERMAL GROWTH FACTOR; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISOLONE SODIUM PHOSPHATE; PROBIOTIC AGENT; PURINE DERIVATIVE; SALAZOSULFAPYRIDINE; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL SUPPRESSION; ADULT; AGRANULOCYTOSIS; ARTHROPATHY; ASEPTIC NECROSIS; BIOLOGICAL THERAPY; BLEEDING; BLOOD DYSCRASIA; CATARACT; CEREBRAL BLINDNESS; CHILD; CHILD GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CONFUSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DIARRHEA; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DYSPEPSIA; DYSPLASIA; DYSPNEA; EDEMA; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FIRST PASS EFFECT; HEADACHE; HEPATITIS; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOCHOLESTEROLEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; INTESTINE SURGERY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOMA; MALAISE; MALIGNANT TRANSFORMATION; MOOD DISORDER; MOTOR DYSFUNCTION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; OSTEOPENIA; PANCREATITIS; PARESTHESIA; PURPURA; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SIDE EFFECT; SINUSITIS; SKIN BRUISING; SORE THROAT; SPEECH DISORDER; SPERMATOZOON ABNORMALITY; STRIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THORAX PAIN; TUBERCULOSIS; ULCERATIVE COLITIS; VERTIGO; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BLOOD COMPONENT REMOVAL; CHILD; CLINICAL TRIALS; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; PROBIOTICS;

EID: 0347286795     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.1.37     Document Type: Review

References (121)

1. EHLIN A, MONTGOMERY S, EKBOM A, POUNDER R, WAKEFIELD A. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut (2003) 58:1117-1121.
2. SAWCZENKO A, SANDHU BK, LOGAN RF et al.: Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet (2001) 357:1093-1094.
3. WATTS DA and SATSANGI J: The genetic jigsaw of inflammatory bowel disease. Gut (2002) 50(Suppl. 3):III31-III36.
4. HYAMS JS, DAVIS P, GRANCHER K et al.: Clinical outcome of ulcerative colitis in children. J. Pediatr. (1996) 129:81-88.
5. ESCHER JC, TAMINIAU JA, NIEUWENHUIS EE, BULLER HA, GRAND RJ: Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm. Bowel. Dis. (2003) 9:34-58.
6. SPRAY C, DEBELLE GD, MURPHY MS: Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatrica (2001) 90:400-405.
7. BEATTIE RM, WALKER-SMITH JA, MURCH SH: Indications for investigation of chronic gastrointestinal symptoms. Arch. Dis. Child. (1995) 73:354-355.
8. KHAN K, SCHWARZENBERG SJ, SHARP H, GREENWOOD D, WEISDORF-SCHINDELE S: Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm. Bowel. Dis. (2002) 8:325-329.
9. RUEMMELE FM, TARGAN SF, LEVY G et al.: Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 115:822-829.
10. JOOSSENS S, REINISCH W, VERMEIRE S et al.: The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 122:1242-1247.
11. WASHINGTON K, GREENSON JK, MONTGOMERY E et al.: Histopathology of ulcerative colitis in initial rectal biopsy in children. Am. J. Surg. Pathol. (2002) 26:1441-1449.
12. KUNDHAL PS, STORMON MO, ZACHOS M et al.: Gastral antral biopsy in the differentiation of pediatric colitides. Am. J. Gastroenterol. (2003) 98:557-561.
13. ABDULLAH BA, GUPTA SK, CROFFIE JM et al.: The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease: a 7-year study. J. Pediatr. Gastroenterol. Nutr. (2002) 35:636-640.
14. HABER HP, BUSCH A, ZIEBACH R et al.: Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J. Ultrasound Med. (2002) 21:375-382.
15. BARABINO A, GATTORNO M, CABRIA M et al.: 99mTc-white cell scanning to detect gut inflammation in children with inflammatory bowel diseases or spondyloarthropathies. Clin. Exp. Rheumatol. (1998) 16:327-334.
16. BRUNO I, MARTELOSSI S, GEATTI O et al.: Antigranulocyte monoclonal antibody immunoscintigraphy in inflammatory bowel disease in children and young adolescents. Acta Paediatr. (2002) 91:1050-1055.
17. CHARRON M, DEL ROSARIO FJ, KOCOSHIS SA: Pediatric inflammatory bowel disease: assessment with scintigraphy with 99mTc white blood cells. Radiology (1999) 212:507-513.
18. GHOSH S, SHAND A, FERGUSON A: Ulcerative colitis. Br. Med. J. (2000) 320:1119-1123.
19. BEATTIE RM, NICHOLLS SW, DOMIZIO P, WILLIAMS CB, WALKER-SMITH JA: Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. (1996) 22:373-379.
20. OTLEY A, SMITH C, NICHOLAS D et al.: The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2002) 35:557-563.
21. SUTHERLAND L, MACDONALD JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. (2003) CD000543.
22. FERRY GD, KIRSCHNER BS, GRAND RJ et al.: Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J. Pediatr. Gastroenterol. Nutr. (1993) 17:32-38.
23. PRUITT R, HANSON J, SAFDI M et al.: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97:3078-3086.
24. SUTHERLAND L, ROTH D, BECK P, MAY G, MAKIYAMA K: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. (2002) CD000544.
25. BARDEN L, LIPSON A, PERT P and WALKER-SMITH JA: Mesalazine in childhood inflammatory bowel disease. Aliment. Pharmacol. Ther. (1989) 3:597-603.
26. ARDIZZONE S, PORRO GB: Comparative tolerability of therapies for ulcerative colitis. Drug Saf. (2002) 25:561-582.
27. ALSTEAD EM, NELSON-PIERCY C: Inflammatory bowel disease in pregnancy. Gut (2003) 52:159-161.
28. RANSFORD RA, LANGMAN MJ: Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut (2002) 51:536-539.
29. SANDBORN WJ, HANAUER SB: Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther. (2003) 17:29-42.
30. JARNEROT G, ROLNY P, SANDBERG-GERTZEN H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology (1985) 89:1005-1013.
31. HANAUER SB and PRESENT DH: The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. (2003) 3:81-92.
32. LOFBERG R, DANIELSSON A, SUHR O et al.: Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology (1996) 110:1713-1718.
33. KELLER R, STOLL R, FOERSTER EC, GUTSCHE N, DOMSCHKE W: Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment. Pharmacol. Ther. (1997) 11:1047-1052.
34. CAMPIERI M, ADAMO S, VALPIANI D et al.: Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment. Pharmacol. Ther. (2003) 17:1471-1480.
35. TURUNEN UM, FARKKILA MA, HAKALA K et al.: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology (1998) 115:1072-1078.
36. GREENBLOOM SL, STEINHART AH, GREENBERG GR: Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. J. Gastroenterol. (1998) 12:53-56.
37. BALL P, MANDELL L, NIKI Y, TILLOTSON G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. (1999) 21:407-421.
38. DUBINSKY MC, YANG H, HASSARD PV et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 122:904-915.
39. GEORGE J, PRESENT DH, POU R, BODIAN C and RUBIN PH: The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am. J. Gastroenterol. (1996) 91:1711-1714.
40. ARDIZZONE S, MOLTENI P, IMBESI V et al.: Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J. Clin. Gastroenterol. (1997) 25:330-333.
41. HAWTHORNE AB, LOGAN RF, HAWKEY CJ et al.: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br. Med. J. (1992) 305:20-22.
42. VERHAVE M, WINTER HS and GRAND RJ: Azathioprine in the treatment of children with inflammatory bowel disease. J. Pediatr. (1990) 117:809-814.
43. KADER HA, MASCARENHAS MR, PICCOLI DA, STOUFFER NO, BALDASSANO RN: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. (1999) 28:54-58.
44. BARABINO A, TORRENTE F, VENTURA A et al.: Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment. Pharmacol. Ther. (2002) 16:1125-1130.
45. DUBINSKY MC, LAMOTHE S, YANG HY et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 118:705-713.
46. SCHWAB M, SCHAFFELER E, MARX C et al.: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics (2002) 12:429-436.
47. NIELSEN OH, VAINER B, RASK-MADSEN J: Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther. (2001) 15:1699-1708.
48. LOWRY PW, FRANKLIN CL, WEAVER AL et al.: Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 49:656-664.
49. KIRSCHNER BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology (1998) 115:813-821.
50. MARKOWITZ J, GRANCHER Y, MANDEL F, DAUM F: Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am. J. Gastroenterol. (1993) 88:44-48.
51. FUENTES D, TORRENTE F, KEADY S et al.: High-dose azathioprine in children with inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17:913-921.
52. FRASER AG, ORCHARD TR and JEWELL DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut (2002) 50:485-489.
53. OREN R, ARBER N, ODES S et al.: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology (1996) 110:1416-1421.
54. PAOLUZI OA, PICA R, MARCHEGGIANO A et al.: Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther. (2002) 16:1751-1759.
55. LICHTIGER S, PRESENT DH: Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet (1990) 336:16-19.
56. LOFTUS CG, LOFTUS EV Jr, SANDBORN WJ: Cyclosporin for refractory ulcerative colitis. Gut (2003) 52:172-173.
57. TREEM WR, COHEN J, DAVIS PM, JUSTINICH CJ, HYAMS JS: Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis. Colon Rectum (1995) 38:474-479.
58. BARABINO A, TORRENTE F, CASTELLANO E et al.: The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment. Pharmacol. Ther. (2002) 16:1503-1507.
59. RAMAKRISHNA J, LANGHANS N, CALENDA K, GRAND RJ, VERHAVE M: Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (1996) 22:296-302.
60. BARABINO A, CASTELLANO E, GANDULLIA P, BISCALDI E: A girl with severe fistulizing Crohn's disease. Dig. Liver Dis. (2000) 32:792-794.
61. ROSENCRANTZ R, MOON A, RAYNES H, SPIVAK W: Cyclosporine-Induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors. Am. J. Gastroenterol. (2001) 96:2778-2782.
62. PODOLSKY DK: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347:417-429.
63. WIRTZ S, NEURATH MF: Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther. (2003) 10:854-860.
64. BOUSVAROS A, KIRSCHNER BS, WERLIN SL et al.: Oral tacrolimus treatment of severe colitis in children. J. Pediatr. (2000) 137:794-799.
65. BAUMGART DC, WIEDENMANN B, DIGNASS AU: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17:1273-1281.
66. FELLERMANN K, TANKO Z, HERRLINGER KR et al.: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel. Dis. (2002) 8:317-324.
67. HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541-1549.
68. SERRANO MS, SCHMIDT-SOMMERFELD E, KILBAUGH TJ et al.: Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. (2001) 35:823-828.
69. MAMULA P, MARKOWITZ JE, BROWN KA et al.: Infliximab as a novel therapy for pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. (2002) 34:307-311.
70. ACTIS GC, BRUNO M, PINNA-PINTOR M, ROSSINI FP, RIZZETTO M: Infliximab for treatment of steroid-refractory ulcerative colitis. Dig. Liver. Dis. (2002) 34:631-634.
71. GORNET JM, COUVE S, HASSANI Z et al.: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment. Pharmacol. Ther. (2003) 18:175-181.
72. PROBERT CS, HEARING SD, SCHREIBER S et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 52:998-1002.
73. FARRELL RJ, ALSAHLI M, JEEN YT et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
74. KUGATHASAN S, LEVY MB, SAEIAN K et al.: Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol. (2002) 97:1408-1414.
75. SANDBORN WJ: Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology (2003) 124:1140-1145.
76. SANDBORN WJ, HANAUER SB: Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am. J. Gastroenterol. (2002) 97:2962-2972.
77. CREED TJ, NORMAN MR, PROBERT CS et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. Ther. (2003) 18:65-75.
78. VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastroenterol. (2003) 98:369-376.
79. SINHA A, NIGHTINGALE J, WEST KP, BERLANGA-ACOSTA J, PLAYFORD RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. (2003) 349:350-357.
80. SHIMOYAMA T, SAWADA K, HIWATASHI N et al.: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J. Clin. Apheresis. (2001) 16:1-9.
81. TOMOMASA T, KOBAYASHI A, KANEKO H et al.: Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig. Dis. Sci. (2003) 48:750-754.
82. GIONCHETTI P, RIZZELLO F, HELWIG U et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 124:1202-1209.
83. GUSLANDI M, GIOLLO P and TESTONI PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. (2003) 15:697-698.
84. VENTURI A, GIONCHETTI P, RIZZELLO F et al.: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. (1999) 13:1103-1108.
85. ISHIKAWA H, AKEDO I, UMESAKI Y et al.: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr. (2003) 22:56-63.
86. VERNIA P, ANNESE V, BRESCI G et al.: Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur. J. Clin. Invest. (2003) 33:244-248.
87. HALLERT C, BJORCK I, NYMAN M et al.: Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm. Bowel. Dis. (2003) 9:116-121.
88. FERNANDEZ-BANARES F, HINOJOSA J, SANCHEZ-LOMBRANA JL et al.: Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am. J. Gastroenterol. (1999) 94:427-433.
89. MARSHALL JK, IRVINE EJ: Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am. J. Gastroenterol. (2000) 95:1628-1636.
90. MARSHALL JK, IRVINE EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut (1997) 40:775-781.
91. SCHOON EJ, BLOK BM, GEERLING BJ et al.: Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology (2000) 119:1203-1208.
92. BJARNASON I, MACPHERSON A, MACKINTOSH C et al.: Reduced bone density in patients with inflammatory bowel disease. Gut (1997) 40:228-233.
93. DINCA M, FRIES W, LUISETTO G et al.: Evolution of osteopenia in inflammatory bowel disease. Am. J. Gastroenterol. (1999) 94:1292-1297.
94. HOMIK J, CRANNEY A, SHEA B et al.: Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst. Rev. (2000) CD001347.
95. GREEN TJ, ISSENMAN RM and JACOBSON K: Patients' diets and preferences in a pediatric population with inflammatory bowel disease. Can. J. Gastroenterol. (1998) 12:544-549.
96. BERNSTEIN CN, AMENT M, ARTINIAN L, RIDGEWAY J, SHANAHAN F: Milk tolerance in adults with ulcerative colitis. Am. J. Gastroenterol. (1994) 89:872-877.
97. PFEFFERKORN MD, FITZGERALD JF, CROFFIE JM et al.: Lactase deficiency: not more common in pediatric patients with inflammatory bowel disease than in patients with chronic abdominal pain. J. Pediatr. Gastroenterol. Nutr. (2002) 35:339-343.
98. OLSSON R, DANIELSSON A, JARNEROT G et al.: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology (1991) 100:1319-1323.
99. WILSCHANSKI M, CHAIT P, WADE JA et al.: Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology (1995) 22:1415-1422.
100. FELDSTEIN AE, PERRAULT J, EL YOUSSIF M et al.: Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 38:210-217.
101. OKOLICSANYI L, GROPPO M, FLOREANI A et al.: Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig. Liver Dis. (2003) 35:325-331.
102. LOFTUS EV Jr, AGUILAR HI, SANDBORN WJ et al.: Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology (1998) 27:685-690.
103. BROOME U, LOFBERG R, VERESS B, ERIKSSON LS: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology (1995) 22:1404-1408.
104. BARABINO A, TEGALDO L, CASTELLANO E et al.: Severe attack of ulcerative colitis in children: retrospective clinical survey. Dig. Liver Dis. (2002) 34:44-49.
105. DICKINSON RJ, ASHTON MG, AXON AT et al.: Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology (1980) 79:1199-1204.
106. RIZZELLO F, GIONCHETTI P, VENTURI A, CAMPIERI M: Review article: medical treatment of severe ulcerative colitis. Aliment. Pharmacol. Ther. (2003) 17(Suppl. 2):7-10.
107. MANTZARIS GJ, PETRAKI Y, ARCHAVLIS E et al.: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand. J. Gastroenterol. (2001) 36:971-974.
108. DICKINSON RJ, O'CONNOR HJ, PINDER I et al.: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut (1985) 26:1380-1384.
109. BURKE DA, AXON AT, CLAYDEN SA et al.: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. (1990) 4:123-129.
110. GIONCHETTI P, RIZZELLO F, FERRIERI A et al.: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci. (1999) 44:1220-1221.
111. EADEN JA, MAYBERRY JF: Colorectal cancer complicating ulcerative colitis: a review. Am. J. Gastroenterol. (2000) 95:2710-2719.
112. EADEN J, ABRAMS K, EKBOM A, JACKSON E, MAYBERRY J: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther. (2000) 14:145-153.
113. LIM CH, DIXON MF, VAIL A et al.: Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut (2003) 52:1127-1132.
114. NICHOLLS RJ: Review article: ulcerative colitis - surgical indications and treatment. Aliment. Pharmacol. Ther. (2002) 16(Suppl. 4):25-28.
115. MAHADEVAN U, SANDBORN WJ: Diagnosis and management of pouchitis. Gastroenterology (2003) 124:1636-1650.
116. FONKALSRUD EW, THAKUR A, BEANES S: Ileoanal pouch procedures in children. J. Pediatr. Surg. (2001) 36:1689-1692.
117. RINTALA RJ, LINDAHL HG: Proctocolectomy and J-pouch ileo-anal anastomosis in children. J. Pediatr. Surg. (2002) 37:66-70.
118. ALEXANDER F, SARIGOL S, DIFIORE J et al.: Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis. J. Pediatr. Surg. (2003) 38:78-82.
119. STAVLO PL, LIBSCH KD, RODEBERG DA, MOIR CR: Pediatric ileal pouch-anal anastomosis: Functional outcomes and quality of life. J. Pediatr. Surg. (2003) 38:935-939.
120. NICHOLLS S, VIEIRA MC, MAJROWSKI WH et al.: Linear growth after colectomy for ulcerative colitis in childhood. J. Pediatr. Gastroenterol. Nutr. (1995) 21:82-86.
121. ROBB BW, GANG GI, HERSHKO DD et al.: Restorative proctocolectomy with ileal pouch-anal anastomosis in very young patients with refractory ulcerative colitis. J. Pediatr. Surg. (2003) 38:863-867.